Investigational drug · Phase 2
Sunobinop
Also called: V117957
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alcohol Use Disorder.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
3
Any phase or sponsor naming "Sunobinop"
First trial start
2024
Oct 14, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Sunobinop", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alcohol Use Disorder
Approved drugs for the same conditions: Alcohol dependence · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "Sunobinop" as an intervention, largest first.
- Study of Sunobinop on Alcohol Consumption in Alcohol Use DisorderPivotal-lookingCompleted
Knoa Pharma LLCIndustry
NCT06545916 · 209 participants · Start Oct 14, 2024 · Primary completion May 5, 2026
Drug: Sunobinop; Placebo to match sunobinop · For: Alcohol Use Disorder
Sites: Brooklyn, New York; Columbus, Ohio; Baytown, Texas · 7 sites in all
Imbrium TherapeuticsIndustry
NCT06024642 · 51 participants · Start Jun 30, 2022 · Primary completion May 21, 2024
Drug: V117957; Placebo · For: Overactive Bladder Syndrome
Sites: Tucson, Arizona; Canoga Park, California; Long Beach, California · 12 sites in all
Knoa Pharma LLCIndustry
NCT06545929 · 40 participants · Start Jan 28, 2025 · Primary completion Jul 14, 2025
Drug: Sunobinop; Placebo to match sunobinop · For: Alcohol Use Disorder
Sites: Columbus, Ohio
Newest research
PubMed records naming it or its code names, newest first.
- A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Interactions Between Alcohol and Sunobinop in Healthy Participants.
Harris SC, Shet MS, Cipriano A, et al. · J Clin Psychopharmacol 2026
- Human Abuse Potential of Single Oral Doses of Sunobinop, a Novel, Highly Potent, and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors.
Harris SC, Cipriano A, Whiteside GT, et al. · J Clin Psychopharmacol 2026
- Design, Synthesis, and Pharmacological Characterization of Substituted Quinoxalines as NOP Receptor Ligands.
Kyle DJ, Tsuno N, Tafesse L, et al. · Curr Med Chem 2026
- Efficacy and safety of a selective partial agonist for nociception/orphanin-FQ peptide (NOP) receptors in patients with insomnia disorder.
Whiteside GT, He E, Shet MS, et al. · Br J Clin Pharmacol 2026
- In vitro pharmacological evaluation of the novel NOP receptor partial agonist sunobinop.
Camilotto R, Malfacini D, Pola P, et al. · Biochem Pharmacol 2025
- Evaluation of sunobinop for next-day residual effects in healthy participants.
Cipriano A, Kapil RP, Zhou M, et al. · Front Pharmacol 2024
Also in development for Alcohol Use Disorder
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- MazdutideLY3305677Phase 35 trials
Eli Lilly · Type 2 Diabetes, Obesity, Overweight
- CMND-100MEAIPhase 21 trial
Clearmind Medicine Inc. · Alcohol Use Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.